Vanguard Group’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Vanguard Group’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,483,472	Closed	-$633K	–	4626
2023 Q1	$633K	Buy	2,483,472 +712,450	+40%	+$644K	﹤0.01%	4052
2022 Q4	$2.09M	Sell	1,771,022 -1,455,445	-45%	-$3.06M	﹤0.01%	3638
2022 Q3	$6.58M	Buy	3,226,467 +2,161,758	+203%	+$3.67M	﹤0.01%	3167
2022 Q2	$1.64M	Buy	1,064,709 +19,266	+2%	+$75.3K	﹤0.01%	3893
2022 Q1	$5.28M	Buy	1,045,443 +422,804	+68%	+$1.92M	﹤0.01%	3502
2021 Q4	$3.86M	Buy	+622,639	New	+$5.56M	﹤0.01%	3754

Vanguard Group's PEAR Position: Q2 2023 in Review

Vanguard Group sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 2,483,472 shares — an estimated $633K sold.

Vanguard Group first reported a position in PEAR in Q4 2021 and held it in 6 quarters. The position peaked at $6.58M in Q3 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

Vanguard Group reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Vanguard Group sold 2,483,472 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $633K.
Vanguard Group first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q4 2021 and held it in 6 quarters.
Vanguard Group's Pear Therapeutics, Inc. Class A Common Stock position peaked at $6.58M in Q3 2022.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Vanguard Group's 13F filing for Q2 2023, filed 14 Aug 2023.